InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 280145

Friday, 12/02/2016 8:03:14 PM

Friday, December 02, 2016 8:03:14 PM

Post# of 346386
Reduction in MDSCs (PS Targeting MOA) in Colitis cancers leads to overall survival

http://link.springer.com/article/10.1007/s13277-016-5414-2

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News